Key facts
- Notable investors include Yanghe Investment.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Dayu Tianxia
- ·The full record, as it builds
Funding rounds
No funding rounds for Dayu Tianxia are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dayu Tianxia
Manufacturer of biopharmaceutical products intended to advance antibody-drug conjugate platforms for high-need clinical areas. The company offers preclinical oncology compounds and bioconjugation products, thereby enabling precision treatment development, improved therapeutic efficacy, and scalable innovation in cancer and metabolic disease domains.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Dayu Tianxia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dayu Tianxia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dayu Tianxia in its N-PORT filings yet. We sweep new filings monthly.